Ansell (ANN) H2 2025 earnings summary

Executive summary

• Achieved strong top and bottom-line growth in FY25, with adjusted EPS of US126.1¢ at the upper end of guidance, driven by robust sales and margin expansion in both Industrial and Healthcare segments.

• Successfully integrated the KBU acquisition ahead of schedule, exceeding synergy targets and enhancing the product portfolio.

• Delivered APIP savings of $47m in FY25, with focus shifting to IT and ERP upgrades.

• Sustainability progress includes expanded net zero targets, validation by Science Based Targets initiative, and a 16% reduction in injury frequency.

• Announced on-market share buyback program up to $200 million for FY26.

Financial highlights

• FY25 sales reached $2,003.3m, up 23.7% reported and 7.7% organic constant currency year-over-year.

• EBIT grew to $282.1m, up 44.3% reported and 10.4% organic constant currency; EBIT margin improved to 14.1%, a 200bps increase.

• Adjusted EPS was US126.1¢, at the upper end of guidance; statutory EPS was US69.9¢.

• Dividend per share increased by 30.7% to US50.20¢.

• Net debt/EBITDA reduced to 1.6x at year-end, with strong liquidity and balance sheet flexibility.

• Net CapEx was $68 million, including investment in a new surgical plant in India.

Outlook and guidance

• FY26 adjusted EPS guidance set at US133¢–US145¢, requiring continued earnings growth and reflecting higher sales, productivity, and KBU synergies.

• Pricing actions to fully offset higher US tariffs (~$80m annualized cost); further increases being implemented in H1 FY26.

• Capex planned at $60–70m, focused on automation and sustainability.

• Continued sales growth expected, with solid healthcare demand and selective industrial growth.

• Ongoing productivity initiatives and further KBU synergy delivery anticipated.